Why the study?
Does intracoronary administration of adv-vIL-10 prolong allograft survival in a rat heart transplant model?
Does intracoronary administration of adv-vIL-10 prolong allograft survival in a rat heart transplant model?
Answers are grounded in this paper and cite their sources.
Intracoronary gene transfer of viral IL-10 prolongs heart allograft survival and acts synergistically with cyclosporine A in a rat model of acute rejection.
715 Background: The ability to express genes with potential immunoregulatory capacity could reduce the immunogenicity of allografts and result in long term survival. We recently reported a patient who developed PTLD with systemic EBV infection and experienced long-term allograft survival when all immunosuppression was discontinued. This functionally tolerant state was associated with over expression of vIL-10 in the allograft(Transp. 64: 1578, 1997). In this study, we examine the feasibility of transferring the vIL-10 gene into rat hearts by intracoronary administration and the subsequent effects of delivered vIL-10 on acute heart allograft rejection. Methods & Results: Viral Constructs: First, the adenoviral β-galactosidase vector (adv-β-gal), as a reporter and control gene, and then the vIL-10 vector (adv-vIL-10) was constructed and the cording gene sequences were assessed. Protein synthesis by the adv-β-gal and adv-vIL-10 constructs was confirmed in vitro in infected Cos 7 cells. Heart Transplants: First, we examined the feasibility of gene delivery by injecting the adv-β-gal into a rat donor heart by intracoronary arterial perfusion in a syngeneic model (ACI -> ACI). 2×109 pfu/gm of adv-β-gal particles were perfused into the coronary artery and the graft was preserved in cold Euro-Collins solution for 60 min prior to transplant. Protein synthesis of β-gal in hearts was confirmed by histochemical staining and was still present on day 20. Next, we examined the ability of adv-vIL-10 gene transfection to modify AR in a highly histoincompatible rat heart transplant model (ACI->LEW). We examined 5 groups (Group 1: No Rx, Group 2: adv-β-gal Rx, Group 3: CSA (10mg/kg×1), Group 4: adv-vIL-10, and Group 5: adv-vIL-10 + CSA). The survival of allografts was checked by determining heart beats by palpation. Results are shown in the table below: Conclusions: 1) Intracoronary arterial administration of genes carried by adenoviral vectors into a beating heart can be successfully accomplished. 2) Delivering adv-vIL-10 into donor heart significantly prolongs allograft survival in this highly histoincompatible rat model. 3) Sub-therapeutic doses of CSA do not prolong allograft survival, but act synergistically with adv-vIL-10 to significantly prolong graft survival beyond that achieved with either agent alone.
No takes yet. Share an insight, caveat, or question.
Zuo et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: